marked.bio

Company

HUYABIO International

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 3 trials shown

  1. A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

    Active, not recruiting Phase 1 HUYABIO International Started 2022Primary completion 2026-12 NCT05485974

    HBI-2438

    Advanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing

    KRAS G12CLung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas

  2. A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

    Active, not recruiting Phase 1 HUYABIO International Started 2021Primary completion 2026-12 NCT05163028

    HBI-2376

    Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology

    EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DNon Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor